Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.*
SABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast CancerASH 2025 | Orlando, FL
Dec 6 - 9, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCLSFN 2025 | San Diego, CA
Nov 15 - 19, 2025
Poster
ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy VolunteersISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast CancerISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility DataSITC 2025 | National Harbor, MD
Nov 5 - 9, 2025
Poster
Preclinical Antitumor Activity of Potent and Orally Bioavailable PROTAC HPK1 Degraders as Monotherapy or Combined With an Anti-PD-1 AntibodyAACR-NCI-EORTC 2025 | Boston, MA
Oct 22 - 26, 2025
Poster
Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer ModelsAACR-NCI-EORTC 2025 | Boston, MA
Oct 22 - 26, 2025
Poster
Preclinical Activity of ARV-806, a PROTAC KRAS G12D DegraderESMO 2025 | Berlin, Germany
Oct 17 - 21, 2025
Presentation
TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast Cancer* Vepdegestrant (VEPPANU™) is licensed to Rigel Pharmaceuticals, which holds the exclusive global development, manufacturing, and commercialization rights.